RABI-767 / Panafina - LARVOL DELTA

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Trial completion date: Jun 2026 ➔ Nov 2026 | Trial primary completion date: Jun 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Pancreatitis

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Trial completion date: Mar 2026 ➔ Jun 2026 | Trial primary completion date: Mar 2026 ➔ Jun 2026

Trial completion date • Trial primary completion date • Pancreatitis

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial primary completion date • Pancreatitis

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Trial completion date: Oct 2025 ➔ Feb 2026

Trial completion date • Pancreatitis

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Pancreatitis

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Panafina, Inc. | Initiation date: Feb 2024 ➔ Jun 2024

Trial initiation date • Pancreatitis